Evaluation of characteristics of cancer immunity by serum cytokines of breast cancer patients and search for stratification methods for drug treatment

Evaluation of characteristics of cancer immunity by serum cytokines of breast cancer patients and search for stratification methods for drug treatment - Evaluation of characteristics of cancer immunity by serum cytokines of breast cancer patients and stratification

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000045631

Enrollment

100

Registered

2021-10-15

Start date

2021-10-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Breast cancer patients whose specimens are stored in the Clinical Biobank, Biobank Division, Personalized Medicine Center, Tohoku University Hospital. (2) The stage of cancer does not matter.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Eighteen types of cytokines in stored serum samples (GM-CSF, IFN-gamma, IL-1beta, IL-2, IL-4, IL-5, IL-6, IL-8, IL-9, IL-10, IL-12p70, IL-17A, IL-17F, IL-22, IL-33, TNFalpha, TNF-beta, TSLP) are quantified all at once. The measurement results are collated with patient data (use of anticancer drug, stage, presence / absence / timing of metastasis, blood sampling time) to analyze the relationship with drug intractability.	—

Measure

Time frame

Eighteen types of cytokines in stored serum samples (GM-CSF, IFN-gamma, IL-1beta, IL-2, IL-4, IL-5, IL-6, IL-8, IL-9, IL-10, IL-12p70, IL-17A, IL-17F, IL-22, IL-33, TNFalpha, TNF-beta, TSLP) are quantified all at once. The measurement results are collated with patient data (use of anticancer drug, stage, presence / absence / timing of metastasis, blood sampling time) to analyze the relationship with drug intractability.

—

Countries

Japan

Contacts

Public ContactNoriyasu Hirasawa

Tohoku University Graduate School of Pharmaceutical Sciences

noriyasu.hirasawa.c7@tohoku.ac.jp022-795-6809

Outcome results